Bachem Holding AG (BANB) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Bachem Holding AG stock CHF 27.72, price CHF 79.55, that is 65.2% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range CHF 43.77 – CHF 163.08 · fair‑value band CHF 20.56 – CHF 34.74 · the CHF 79.55 price screens above the CHF 27.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Follow Bachem Holding in your weekly email
Every Wednesday you see whether Bachem Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Show moreShow less
It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Stock analysis
Bachem Holding AG (BANB) currently trades at CHF 79.55, while our model-based Fair Value estimate is CHF 27.72, 65% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of CHF 29.38 per share, and 0 of the 16 models we run sit above the CHF 79.55 price.
Bear case: the Dividend Discount group reads lowest at CHF 7.40, and 16 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: CHF 20.56 (bear) to CHF 34.74 (bull), the price of CHF 79.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bachem Holding AG reported revenue of CHF 695M in FY2025 versus CHF 503M in FY2021, a compound +8.4%/yr. Reported net income was CHF 149M in FY2025, compounding +6.7%/yr from FY2021.
Key figures
Market cap CHF 6.0B Mid · P/E ratio 40.2 · P/S ratio 8.41 · EPS (TTM) CHF 1.98 · Dividend yield 1.1% · Net margin 21.0% · Return on equity 10.6% · Return on assets (EBIT) 8.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −65%, BANB screens richer than that median.
Fair Value models
BearCHF 20.56Fair Value CHF 27.72BullCHF 34.74
Price CHF 79.55 · Downside -65.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (CHF 0.9380 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+13.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.2%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12.2% vs 15.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 22%
News mood ⓘNews mood, the average tone of recent news (29 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Bachem's main strength lies in its expanding peptide manufacturing capacity positioned for sales rebound, while its primary weakness remains negative free cash flow driven by heavy investment burdens.
Main risk: Lower-cost Chinese manufacturers and new entrants might increase supply of GLP-1 peptide APIs and force Western CDMOs like Bachem to lower prices or lose volume from major clients such as Novo Nordisk and Eli Lilly, squeezing margins.
Bull case: Bachem could retain and expand its position by delivering superior quality, regulatory expertise and reliable large-scale supply through long-term contracts and process innovations that differentiate it from lower-cost rivals.
Bear case: If competition intensifies and customers shift to in-house production, Bachem might face persistent overcapacity, price erosion and lower utilization of its new facilities, limiting revenue growth and margin recovery.
Bachem is scaling up peptide manufacturing capacity through Building K and the planned Sisslerfeld site while guiding for 35 to 40 percent local-currency sales growth in 2026. Heavy capex and ramp-up costs are weighing on margins right now even as commercial API volumes are expected to rebound strongly in the second half. Will the company convert this new capacity into sustained revenue growth before the investments pressure returns further?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Top 25%
Fair Value upside−65.2% · Bottom 25%
Profitability
Return on equity (12 months)10.6% · Top 25%
Return on assets7.1% · Top 25%
Net margin (12 months)21.0% · Top 25%
Operating margin (12 months)16.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.3% · Above median
Dividend yield (12 months)1.1% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (12 months)40.2× · Pricier than median
P/B4.09× · Pricier than median
P/S (12 months)8.41× · Pricier than median
EV/EBITDA28.2× · Pricier than median
PEG0.61× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)22· sector 0
PAST (return on equity)43· sector 0
HEALTH (low debt)100· sector 96
DIVIDEND (yield)23· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bachem Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/BANB
Frequently asked questions
Is Bachem Holding AG (BANB) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of CHF 27.72 versus a price of CHF 79.55, about 65% lower (overvalued).
What is the fair value of BANB?
Our model-based fair value for Bachem Holding AG is CHF 27.72 (as of Nov 13, 2026), built from audited fundamentals. The current price: CHF 79.55.
What is the quality score of BANB?
Bachem Holding AG has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bachem Holding AG (BANB)?
Our model-based price target is the fair value of CHF 27.72 (as of Nov 13, 2026) from 16 valuation models. Cautious scenario CHF 20.56, optimistic scenario CHF 34.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Bachem Holding AG stock forecast for 2026?
Our models put fair value at CHF 27.72, about 65% lower versus a price of CHF 79.55 (overvalued). Cautious scenario CHF 20.56, optimistic scenario CHF 34.74. The calculation is refreshed regularly with new filings.
What is the revenue of Bachem Holding AG (BANB)?
Bachem Holding AG reported trailing-twelve-month revenue of about CHF 709M (latest available figure, as of Nov 13, 2026).
Does Bachem Holding AG pay a dividend?
Bachem Holding AG currently shows a dividend yield of 1.13% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of Bachem Holding AG (BANB) and when is the ex-dividend date?
Bachem Holding AG pays a dividend of CHF 0.9 per share a year, a dividend yield of 1.1%. The last ex-dividend date was May 4, 2026. A dividend has been paid every year since at least 1999. The payout ratio is 45.5% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Bachem Holding AG (BANB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bachem Holding AG it is CHF 27.72 per share (as of Nov 13, 2026), against a price of CHF 79.55. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Bachem Holding AG stock overvalued or undervalued in 2026?
As of Nov 13, 2026, BANB trades above its calculated fair value: price CHF 79.55, fair value CHF 27.72, a gap of about −65% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BANB?
No. The price is what the market pays today (CHF 79.55); the fair value is what the company's own numbers justify (CHF 27.72). For Bachem Holding AG the two are CHF 51.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bachem Holding AG worth?
The market values Bachem Holding AG at about CHF 6.0B (market capitalisation, as of Nov 13, 2026). Per share that is CHF 79.55; our models calculate a fair value of CHF 27.72 per share.
What do the bullish and bearish scenarios say about BANB?
Our models span a range for Bachem Holding AG: cautious scenario CHF 20.56, base CHF 27.72, optimistic CHF 34.74 per share (as of Nov 13, 2026, price CHF 79.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BANB?
Bachem Holding AG trades at a price-to-earnings ratio of 40.2 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 27.72 is built from several models across several years. Other multiples: PEG 0.6, P/B 4.1, P/S 8.4, EV/EBITDA 28.2.
What is the PEG ratio of BANB?
The PEG ratio of Bachem Holding AG is 0.61 (P/E divided by earnings growth, as of Nov 13, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Bachem Holding AG (BANB)?
Balance-sheet figures for Bachem Holding AG (as of Nov 13, 2026): return on equity 10.6%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is BANB from its 52-week high?
Bachem Holding AG trades at CHF 79.55, about 8% below its 52-week high of CHF 86.00 and 64% above the low of CHF 48.42 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 27.72 is for.
Which stocks are comparable to Bachem Holding AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bachem Holding AG stock attractive at the current price?
The data as of Nov 13, 2026: price CHF 79.55, calculated fair value CHF 27.72 (−65%), Quality Score 56/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BANB calculated?
We run Bachem Holding AG through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 27.72 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.3% above its aggregate fair value. Bachem Holding AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bachem Holding AG (BANB)?
The closing price on Nov 13, 2026 was CHF 79.55. Our model-based fair value is CHF 27.72, about 65% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bachem Holding AG right now?
The price sits above even our optimistic bull case (CHF 34.74). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Bachem Holding AG (BANB) come from?
Earnings per share at Bachem Holding AG grew +14.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.7 %, EBIT margin +1.8 %, tax rate +0.8 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bachem Holding AG
How large is the market capitalisation of Bachem Holding AG (BANB)?
The market capitalisation of Bachem Holding AG is CHF 6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bachem Holding AG (BANB)?
The price-to-sales ratio of Bachem Holding AG is 8.41 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bachem Holding AG (BANB)?
Earnings per share at Bachem Holding AG are CHF 1.98 (price ÷ EPS = P/E 40.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bachem Holding AG (BANB)?
The dividend yield of Bachem Holding AG is 1.1% (payout 45.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bachem Holding AG (BANB)?
The net margin of Bachem Holding AG is 21.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bachem Holding AG (BANB)?
The return on equity (ROE) of Bachem Holding AG is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bachem Holding AG (BANB)?
On an EBIT basis the return on assets of Bachem Holding AG is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bachem Holding AG (BANB)?
The operating margin of Bachem Holding AG is 16.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bachem Holding AG (BANB)?
Revenue at Bachem Holding AG is growing +4.3% versus a year earlier (3y avg +9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bachem Holding AG (BANB) generate?
The free cash flow of Bachem Holding AG is −CHF 48.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bachem Holding AG (BANB) carry?
The net debt of Bachem Holding AG is CHF 26.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bachem Holding AG in the live analysis
One click puts Bachem Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 13, 2026